ATE462697T1 - Bisaryl-sulfonamide - Google Patents

Bisaryl-sulfonamide

Info

Publication number
ATE462697T1
ATE462697T1 AT05790029T AT05790029T ATE462697T1 AT E462697 T1 ATE462697 T1 AT E462697T1 AT 05790029 T AT05790029 T AT 05790029T AT 05790029 T AT05790029 T AT 05790029T AT E462697 T1 ATE462697 T1 AT E462697T1
Authority
AT
Austria
Prior art keywords
pparδ
pparγ
prevention
compounds
treatment
Prior art date
Application number
AT05790029T
Other languages
English (en)
Inventor
Philippe Bergeron
Christopher N Farthing
Stuart D Jones
John W Liebeschuetz
Sarah E Lively
Lawrence R Mcgee
Sharon Mckendry
David Sheppard
Stephen C Young
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE462697T1 publication Critical patent/ATE462697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05790029T 2004-08-12 2005-08-11 Bisaryl-sulfonamide ATE462697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60157804P 2004-08-12 2004-08-12
PCT/US2005/028673 WO2006020830A2 (en) 2004-08-12 2005-08-11 Bisaryl-sulfonamides

Publications (1)

Publication Number Publication Date
ATE462697T1 true ATE462697T1 (de) 2010-04-15

Family

ID=35908167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790029T ATE462697T1 (de) 2004-08-12 2005-08-11 Bisaryl-sulfonamide

Country Status (8)

Country Link
US (2) US7544702B2 (de)
EP (1) EP1786782B1 (de)
AT (1) ATE462697T1 (de)
AU (1) AU2005272786B2 (de)
CA (1) CA2576993C (de)
DE (1) DE602005020313D1 (de)
ES (1) ES2343640T3 (de)
WO (1) WO2006020830A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
ATE462697T1 (de) 2004-08-12 2010-04-15 Amgen Inc Bisaryl-sulfonamide
JP5128603B2 (ja) * 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
CN101863830B (zh) * 2010-06-22 2012-07-25 浙江科源化工有限公司 2-氨基-5-溴异烟酸的合成方法
CN102321016B (zh) * 2011-07-29 2013-04-10 山东轻工业学院 5-溴-2-羟基异烟酸甲酯的合成方法
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN104093716B (zh) * 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2970156B1 (de) 2013-03-15 2018-07-25 Genentech, Inc. Substituierte benzoxazole und verfahren zur verwendung davon
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3854782A1 (de) 2016-03-30 2021-07-28 Genentech, Inc. Substituierte benzamide und verfahren zur verwendung davon
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
CN113773247A (zh) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 一种2-氨基-5-碘吡啶的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB824598A (en) 1957-02-14 1959-12-02 Rhone Poulenc Sa Improvements in or relating to new phenthiazine derivatives and processes for their preparation
BE577515A (fr) 1959-04-09 1959-10-09 Henri Morren Dérives de pyridazine.
US4096264A (en) * 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
EP0173361B1 (de) 1984-08-11 1988-10-19 Agfa-Gevaert N.V. Organische Verbindungen zur Verwendung in einem Farbdiffusionsübertragungsverfahren und solche Verbindungen enthaltende photographische Elemente
CS254541B1 (cs) * 1986-05-04 1988-01-15 Alois Novacek Sulfonamidy na bázi trimethoprimu
US5112971A (en) 1988-08-10 1992-05-12 Sumitomo Chemical Company, Limited Anthraquinone dye compounds having fibers reactive group
FR2650275A1 (fr) * 1989-07-28 1991-02-01 Shimi Ibrahim Nouveaux derives sulfamides, leur procede d'obtention et leur application comme medicament
US5403816A (en) * 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH10114744A (ja) * 1996-08-22 1998-05-06 Takeda Chem Ind Ltd アミノグアニジンヒドラゾン誘導体、その製法及び剤
CA2276288A1 (en) 1996-12-31 1998-07-09 Laszlo Nagy Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
CZ289425B6 (cs) 1998-05-20 2002-01-16 Eli Lilly And Company Imidazo[1,2-a] pyridinové sloučeniny, jejich pouľití a farmaceutický přípravek s jejich obsahem
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
AU2871900A (en) * 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
MXPA01013199A (es) 1999-06-30 2003-08-20 Tularik Inc Compuestos para la modulacion de la actividad de ppary.
WO2001017994A1 (en) 1999-09-08 2001-03-15 Glaxo Group Limited Oxazole ppar antagonists
JP2001083656A (ja) 1999-09-13 2001-03-30 Konica Corp プリントアウトを改良した熱現像感光材料
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
DE69923718T2 (de) 1999-09-24 2006-01-12 Kyorin Pharmaceutical Co., Ltd. Ppar-alpha und ppar-gamma-hemmer
ES2265435T3 (es) * 2000-06-28 2007-02-16 Amgen Inc. Moduladores benzotiazolilo de ppar-gamma.
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP4269052B2 (ja) 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
PA8594401A1 (es) 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
EP1651595A2 (de) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitinligaseinhibitoren
ATE462697T1 (de) 2004-08-12 2010-04-15 Amgen Inc Bisaryl-sulfonamide

Also Published As

Publication number Publication date
CA2576993A1 (en) 2006-02-23
EP1786782B1 (de) 2010-03-31
US7893077B2 (en) 2011-02-22
EP1786782A2 (de) 2007-05-23
AU2005272786B2 (en) 2011-12-22
US20090221584A1 (en) 2009-09-03
US20060084802A1 (en) 2006-04-20
US7544702B2 (en) 2009-06-09
CA2576993C (en) 2013-09-24
DE602005020313D1 (de) 2010-05-12
WO2006020830A3 (en) 2007-04-12
WO2006020830A2 (en) 2006-02-23
AU2005272786A1 (en) 2006-02-23
ES2343640T3 (es) 2010-08-05

Similar Documents

Publication Publication Date Title
ATE462697T1 (de) Bisaryl-sulfonamide
EP2174360A4 (de) Wandler mit elektroaktivem polymer für anwendungen der sensorischen rückmeldung
MX2008011874A (es) Composiciones estabilizadas de polipeptidos.
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TWI346660B (de)
EP2248430A3 (de) Nahrungsmittel mit probiotischem und isoliertem Beta-Glucan und Verwendungsverfahren dafür
BRPI0820297B8 (pt) instrumentos para realizar um procedimento operatório em uma junta
TW200705255A (en) Ring management
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
AT502926A3 (de) Sprunggelenksprothesenelemente
WO2006122187A3 (en) Treating and evaluating inflammatory disorders
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
TW200606483A (en) Methods for rotationally stabilizing contact lenses
WO2009032754A3 (en) Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2008063931A3 (en) Bituminous emulsions
CY1111864T1 (el) Παραγωγα του ενζυμου που διεγειρει nf-καππαβ, παρασκευη αυτων και χρηση αυτων
NO20070440L (no) Behandling av nevropatisk smerte, fibromyalgi eller revmatoid artritt
WO2009046229A3 (en) Animal waste removal device
GB2464417B (en) Security deterrent mark and methods of forming the same
ATE451663T1 (de) Dokument mit einem elektronischen gerät
WO2006098998A3 (en) Methods and compositions for modulating vascular integrity
ATE357967T1 (de) Emulsionen mit oberflächenmodifizierten organischen molekülen
TW200613328A (en) Polymeric materials, which contain inorganic solids, and methods for the production thereof
ATE404102T1 (de) Mechanismus zum langsamen schliessen von toilettendeckeln

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties